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Substance P is a representative of a group of amphiphilic neuropeptides which act as mast cell secretagogues. 
Our experiments with some new substance P derivatives suggest hat these effects are dependent on two 
structural elements: (i) a hydrophobic chain which is not essentially a peptide, and (ii) a hydrophilic part 
with two positively charged amino acids. The mast cell triggering effect is unlikely to be mediated by a selec- 
tive substance P receptor, but has strong similarities to the mode of action of polycations. 
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1. INTRODUCTION 
A number of different amphiphilic neuropep- 
tides receptor agonists were found to induce 
mediator release from rat peritoneal mast cells via 
non-cytolytic mechanisms. These peptides are 
substance P, neurotensin [ 1,2], bradykinin [ 11, 
somatostatin, vasoactive intestinal polypeptide [2], 
and dynorphin [3]. However, substance P an- 
tagonists [1,2], LHRH antagonists [4] and IgE 
fragments [5] are amphiphilic peptides which also 
act as mast cell secretagogues. 
Except for neurotensin, the effective doses are in 
the micromolar range and clear-cut evidence for 
the presence of the corresponding specific mem- 
brane receptor at the mast cell membrane is lack- 
ing. Consequently, a receptor-independent mode 
of mast cell triggering may depend on structural 
properties common to all of these peptides. Based 
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on previous work on structure-activity relation- 
ships (e.g. [1,6,7]), we put forward these 
hypotheses by examining the histamine-releasing 
effect of a number of accordingly designed 
substance P (SP) fragments and analogues, among 
them five representatives of a new group of SP 
derivatives composed of an SP-related N-terminal 
tetrapeptide and non-peptide chains. 
2. MATERIALS AND METHODS 
2.1. Histamine release 
Peritoneal mast cells were obtained from male 
Wistar rats (400-500 g) and male Golden hamsters 
(200-250 g) as described [7] and used without fur- 
ther purification if not stated otherwise. The 
histamine liberation assay was performed as in [7] 
using a tyrode of the following composition (mM): 
130 NaCI, 2.7 KCl, 5.6 glucose, 0.1 CaC12, 1 
MgS04, 10 Hepes, pH 7.4. 
Briefly, 11000 mast cells per sample were in- 
cubated in polypropylene tubes with the cor- 
responding releasing agent for 10 min at 37°C 
subsequent o temperature equilibration (5 min). 
The peptide-induced histamine release was com- 
pleted within less than 1 min. Each test was per- 
formed in quadruplicate. From dose-response 
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curves, each consisting of 6-9 points, the concen- 
tration of the histamine-releasing agent to induce 
50% of the maximal response (EDso) was 
calculated and expressed as pDz = -log EDso. 
Spontaneous histamine release was less than 10% 
and was subtracted from the induced release. 
2.2. Peptides and histamine liberators 
The peptides used here were predominantly syn- 
thesized by conventional peptide synthesis in solu- 
tion. This was previously described in detail for the 
following compounds: SP, SP(5-11) peptide 
amide, [Met(O)“]-SP, [Met(Oz)“]-SP [8]; [Tyr*]- 
SP [9]; [Nle”]-SP, [Cpa7,8,Nle11]-SP [lo]; and 
N”,N’-bis(gluconyl)-SP( 1- 11). The synthesis of N- 
terminal tetrapeptides and [D-Phe9]-SP will be 
published elsewhere. 
SP( 1 -4)-NH-(CH2)2-NH-Cr7Hss and SP( 1-4)- 
(EAhx)d amide were synthesized by stepwise 
elongation in a two-phase system using Fmoc- 
amino acid chlorides [12]. The purity of the pep- 
tides used in this study was 95-98% according to 
HPLC analysis. 
Histamine liberators were obtained from the 
following sources: Poly(L-lysin) (Acris), mellitin 
(Serva), protamine sulphate (Hoffmann-La 
Roche), A23187 (Calbiochem), palytoxin (gift 
from Professor Habermann, Giessen, FRG), com- 
pound 48180 (Sigma), 
The retention times of SP and its derivatives 
were determined using a LiChrosorb RP 18 col- 
umn which was operated by a Shimadzu LCdA 
HPLC equipment and expressed relative to SP 
(SP= 1). 
3. RESULTS 
The amino acid sequence of SP is Arg-Pro-Lys- 
Pro-Gln-Gln-Phe-Gly-Leu-Met-NH2, this being 
the amidated, naturally occurring form. In a first 
series of experiments, the pD2 values (pD2 = - log 
EDso) of the histamine-releasing effect of a 
number of SP derivatives were determined using 
both rat and hamster peritoneal mast cells. The lat- 
ter cells were found to be less responsive. Substitu- 
tions which increase the hydrophobicity of the 
C-terminal heptapeptide ([Nle”]-SP, [Cpa7*8, 
Nle”]-SP, [D-Phe9]-SP) have little effect on the 
pD2 value, whereas analogues with decreased 
hydrophobicity in the same region ([Tyr’]-SP, 
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Fig. 1. The histamine-releasing activity of SP derivatives 
correlates with the relative hydrophobicity of the whole 
molecule, which was determined by HPLC as described 
in section 2. Modifications were restricted to the 
hydrophobic, C-terminal part of SP: 1, [Met(O)“]-SP, 
2, [Met(Oz)“]-SP; 3, [Tyr’]-SP; 4, SP; 5, [Nle”]-SP; 6, 
[Cpa7~8,Nle”]-SP; 7, [D-Phe’]-SP. The maximal 
histamine release was between 60 and 75% of the total. 
Closed points: rat peritoneal mast cells; Spearman-Rang 
correlation coefficient r, = 1.0; open points: hamster 
peritoneal mast cells, r, = 0.955, p < 0.01 (means of 2-4 
experiments f SE). 
[Met(O)“]-SP, [Met(Oz)“]-SP) show a diminution 
of the histamine-releasing potency of the peptide 
(fig.1). The blockade of two positive charges in the 
Neither the N-terminal tetrapeptide SP(l-4) and 
N-terminal 
its derivatives (SP(l-4) amide, [Lys’]-SP(l-4), 
[Ac-Arg’ ,Lys(Ac)3]-SP( l-4)) nor the C-terminal 
segment [W,W-bis(gluconyl)-SP] 
heptapeptide SP(5-11) induced histamine release 
renders SP inactive up to a concentration of 
from both rat and hamster mast cells in the con- 
centration range 5 x 10-7-10-4 M. 
1O-4 M. 
The substitution of the C-terminal pentapeptide 
SP(5-11) by different non-peptide chains led to a 
group of hybrid compounds which act as 
secretagogues via a non-cytolytic, energy- 
dependent mechanism in the concentration range 
examined. This was shown by the absence of any 
effect after pretreatment of the mast cells with an- 
timycin A (2pM) in the absence of glucose. The 
three dodecylamine derivatives are up to 50-fold 
more potent histamine releasers than SP itself and 
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Fig.2. Correlation between the pD2 values for the effect 
of SP derivatives on rat and hamster peritoneal mast 
cells. For compounds 1-7 see fig.1. The numbers 8-12 
represent the following new hybrid compounds: 8, 
SP(l-4)-NH-C,zHzs; 9, [Dhp4]-SP(l-4)-NH-C,zHzs; 
10, [Lys’]-SP(l-4)-NH-CIzHzs; 11, SP(l-4)-NH- 
(CHz)z-NH-C17H3s; 12, SP(l-4)-NH-(cAhx)4. The 
maximal histamine release of 8-12 was between 70 and 
80% of the total. The linear regression coefficient for 
the bottom regression line was r = 0.908, p < 0.001. 
Closed points, peptide derivatives; open points, hybrid 
compounds (means of 2-5 experiments + SE). 
do not fit into the correlation of the pD2 values of 
the other SP derivatives as shown in fig.2. The 
results were nearly identical if purified rat 
peritoneal mast cells (90-95% purity) were used 
(Repke et al., in preparation). 
Dodecylamine acts as a lytic agent by an an- 
timycin A-insensitive mechanism on both hamster 
(ED50 = 8.7 + 2.3 FM) and rat peritoneal mast 
cells (EDso = 8.0 f 0.1 PM). 
The substitution of SP(5-11) by -NH- 
(CH~)Z-NH-C,~H~~ and -NH-(cAhx)d led to a 
medium and a weak histamine releaser espective- 
ly, which fit into the linear correlation of the pD2 
values of the peptide derivatives of SP (fig.2). 
As shown in fig.3, hamster mast cells respond 
0 Rat •d Hamster 
Fig.3. Rat peritonea1 mast cells respond more effectively 
to polycation histamine liberators than hamster mast 
cells do. This is not the case with the other secretagogues 
used (means of 2-4 experiments -t SE). The maximal 
histamine release was between 60 and 80% except for the 
lytic agent mellitin (95% of total). 
weakly to polycationic secretagogues when com- 
pared with the same cell type of the rat. With other 
histamine releasers, however, an inverse potency 
ratio was found. 
4. DISCUSSION 
The most comprehensive collection of data on 
the structure-activity relationship of a neuro- 
peptide-induced mediator release from mast cells 
has been accumulated for SP [1,7]. The stimula- 
tion of mast cells by presynaptically released SP 
plays a physiological role in the frame of neuro- 
genie inflammation [ 131. Therefore, this peptide 
was chosen as a model compound in our studies. 
The following conclusions can be drawn from 
our results. 
(i) Neither the hydrophilic nor the hydrophobic 
part of the SP molecule or its derivatives can trig- 
ger non-cytolytic histamine release. This confirms 
previous data from others [1,7]. 
(ii) Amino acid substitutions resulting in in- 
creased hydrophobicity of the C-terminal part of 
SP slightly increase the mast cell triggering potency 
whereas the incorporation of hydrophilic residues 
has the inverse effect. This fits into the previously 
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described strong agonistic effects of the 
hydrophobic SP receptor antagonists on rat mast 
cells [ 1,2]. 
(iii) The blockade of two of the three positive 
charges converts SP into an inactive compound 
although the N-terminal part is still hydrophilic. A 
minimal number of two positively charged amino 
acids appears to be essential for the mast cell trig- 
gering effect [ 1,6,7,15]. However, the nature of 
these amino acids does not seem to be crucial since 
compounds S-10 of fig.2 are nearly equipotent. 
(iv) Although of essential importance for the in- 
teraction of SP and its derivatives with the present- 
ly known SP receptor subtypes [14], the amino 
acid composition of the hydrophobic pentapeptide 
SP(5-11) is irrelevant for its mast cell triggering 
action. This is demonstrated by the new hybrid 
compounds, three of which are among the most 
potent histamine releasers described so far. In ac- 
cord with (ii), the derivative with the more 
hydrophilic chain [SP(l-4)-(EAhx)4 amide] is a 
very weak histamine releaser. 
(v) As detailed in [15], the histamine release in- 
duced by the model compound SP(l-4)-NH- 
CizHzs is completed within less than 30 s, requires 
temperatures above 16”C, is independent of exter- 
nal calcium, and can be inhibited by amphiphilic 
compounds with one or two positive charges. So 
far, this model compound was found to behave 
similarly to SP in every respect. 
(vi) The dodecylamine derivatives are much more 
potent on rat mast cells compared to hamster mast 
cells. This difference might be due to the triggering 
of calcium influx rather than to protein kinase C 
activation (Repke, H. et al., in preparation). 
(vii) Hamster peritoneal mast cells are much less 
responsive towards polycations but not to other 
histamine liberators when compared to the cor- 
responding cell type from the rat. Since the same 
difference was found with SP and all of its 
derivatives, we consider this as a further clue that 
the mode of action of these compounds is similar 
to that of polycations [15]. 
The hydrophobic amino acids of SP and other 
amphiphilic neuropeptides are likely to form an (Y- 
helix after insertion into a lipid membrane [16,171. 
An association with the hydrophobic phase of the 
membrane can also be expected for the dodecyl 
and stearyl chains used in four of our hybrid com- 
pounds. It might be speculated that the three 
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positive charges within the hydrophilic part of 
these compounds and SP itself become associated 
with negatively charged components of the mem- 
brane surface, thus resulting in their decreased 
mobility which might be the initial event of mast 
cell activation similar to the action of polycations. 
Previously, peptides of the same structural feature 
as discussed above were found to decrease the 
mobility of band 3 proteins or erythrocytes. The 
extent of this effect was directly correlated with 
their histamine-releasing potency, [5]. 
This receptor-independent mechanism of mast 
cell activation by SP may be physiologically rele- 
vant at high local peptide concentrations in the 
vicinity of presynaptic terminals [13] and may also 
apply for the action of other neuropeptides on 
mast cells [l-6]. 
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